According to Outi Vaarala, Orion has proven its capacity for novel and creative drug discovery. The pharmaceutical company convinced the well-known immunologist to return home to Finland to lead an innovative research project for a cancer drug.
Going abroad was an important career move for Sara Sammallahti. A grant of EUR 50,000 from the Orion Research Foundation made it possible for her to join a group of Dutch and American researchers. Sammallahti is studying the effects of the mother’s well-being during pregnancy on the brain of the foetus.
A novel screening method enables faster and more accurate measurement.
The Phase 2 clinical trial (LEVALS) show encouraging results: in 66 patients supine SVC was significantly higher after 14 days treatment on oral levosimendan compared to placebo.
Thanks to biosimilars, an increasing number of patients can receive effective care at a lower pharmaceutical cost.
In Universum’s student survey on ideal workplaces Orion was ranked third by natural science students.